The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.
Summit Therapeutics’ partner Akeso has secured China’s NMPA authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous NSCLC patients.
Mereo BioPharma and Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for AATD-LD.
Launching a product across Europe’s fragmented healthcare systems presents unique challenges that first-timers are often unprepared for, say experts from Cencora.
Jazz Pharmaceuticals is to acquire Actio Biosciences in a deal that includes an $820m upfront payment and up to $500m in additional contingent payments.
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled R&D partnership to explore new treatments for autoimmune and inflammatory diseases.
Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
The US FDA has granted breakthrough therapy designation to Lilly olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.
IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to $488.3m, giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
miRecule has signed a research collaboration with Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted RNA therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Cell and gene therapy manufacturers are partnering with specialist technology companies to address the challenges associated with scaling complex therapies.
BioMarin Pharmaceutical and n-Lorem Foundation have entered a collaboration and licence agreement to develop an investigational ASO therapy for ReNU syndrome.
In this issue: Misumi Americas makes US manufacturing strategic priority, the celebrity brand ambassador rise in pharma, AI in the hospital pharmacy, and more.
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and ML.
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.
Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular diseases.
Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has received approval from the EC to expand the use of Crysvita for treating XLH in infants aged one month to one year across the EU and European Economic Area.
Cellares and Papillon Therapeutics have entered into a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for FA, a rare inherited neurodegenerative disorder.
Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.
